Posted by Michael Wonder on 28 Apr 2022
Nocira becomes first company ever to announce breakthrough device designation by the FDA for acute treatment of migraine
27 April 2022 - Nocira's hand held device that uses gentle, controlled puffs of air in the ears for treating migraine attacks is now designated by the FDA as a breakthrough device.
With so many migraine therapies on the market, when someone says they have a breakthrough, patients tend to take it with a grain of salt. Except, of course, when the word "breakthrough" is associated with a special designation by the FDA.
Today, Nocira is pleased to announce its device, which uses gentle, controlled puffs of air in the ears (called "Automated Variable Pulse Insufflation™" or "AVPI"), was officially designated by the FDA as a breakthrough device for the acute treatment of migraine by patients 18 years or older.
